SIGN 146 Cutaneous melanoma

The revision of the SIGN guideline on cutaneous melanoma has been published today, and takes account of new evidence in diagnostic and prognostic indicators, imaging techniques and laboratory investigation and systemic therapy. This evidence based guideline covers:

• prevention, surveillance and genetics
• diagnosis and prognostic indicators
• surgical management and staging
• further investigation and non-surgical staging
• adjuvant treatment of stage II and stage III melanoma
• follow up of patients with stage I, II and III melanoma
• management of advances (unresectable stage IIIC or IV) melanoma
• melanoma in women
• provision of information

It does not address melanomas of non-cutaneous origin such as melanomas arising from mucosae, ocular melanomas and other rare non-cutaneous sites.

Link to Document: http://www.sign.ac.uk/pdf/SIGN146.pdf